FDA – Communications from firms to health care providers (HCPs) regarding scientific information on unapproved uses of approved/cleared medical products: questions and answers guidance for industry
The FDA has issued a final guidance describing the FDA’s enforcement policy regarding certain firm-initiated communications of scientific information on unapproved use(s) of the firm’s approved/cleared medical products to HCPs engaged in prescribing or administering medical products to individual patients.
News reported on the 31st of January 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). FDA – Communications from firms to health care providers (HCPs) regarding scientific information on unapproved uses of approved/cleared medical products: questions and answers guidance for industry. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/13yf0





